Last 2.33 NOK
Change Today +0.05 / 2.19%
Volume 567.6K
BIONOR On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
As of 10:25 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

bionor pharma asa (BIONOR) Snapshot

Open
2.34 NOK
Previous Close
2.28 NOK
Day High
2.34 NOK
Day Low
2.24 NOK
52 Week High
03/13/14 - 4.48 NOK
52 Week Low
04/29/14 - 1.91 NOK
Market Cap
578.6M
Average Volume 10 Days
486.1K
EPS TTM
-0.35 NOK
Shares Outstanding
248.3M
EX-Date
12/12/03
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIONOR PHARMA ASA (BIONOR)

Related News

No related news articles were found.

bionor pharma asa (BIONOR) Related Businessweek News

No Related Businessweek News Found

bionor pharma asa (BIONOR) Details

Bionor Pharma ASA, a biotechnology company, is engaged in developing peptide based vaccines against viral diseases, primarily human immunodeficiency virus (HIV). The company’s HIV vaccine candidates in clinical development include Vacc-4x for reducing viral load and killing virus producing cells; and Vacc-C5 is indicated for the formation of antibodies against HIV in humans. The company is also developing Vacc-HIV, a preclinical phase vaccine, using the combination of Vacc-4x and Vacc-C5 vaccines; and Vacc-Flu, a preclinical phase influenza vaccine. In addition, it is developing vaccines for other viral diseases, including Hepatitis C, cytomegalovirus infection, and human papillomavirus infection. Further, the company provides nutraceutical products, such as Nutri5 and NutriPro. It operates in Norway and Europe, including Russia. The company was formerly known as Nutri Pharma ASA and changed its name to Bionor Pharma ASA in June 2010. Bionor Pharma ASA was founded in 1993 and is based in Oslo, Norway.

10 Employees
Last Reported Date: 11/4/14
Founded in 1993

bionor pharma asa (BIONOR) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: 1.3M NOK
Executive Vice President
Total Annual Compensation: 1.9M NOK
Compensation as of Fiscal Year 2013.

bionor pharma asa (BIONOR) Key Developments

Bionor Pharma ASA Announces Management Changes

Bionor Pharma ASA announced the appointment of Dr. David Horn Solomon as new President and Chief Executive Officer. Dr. Solomon will join the company from Zealand Pharma A/S, where he has served as President and CEO since September 2008. Dr. Solomon succeeds Dr. Anker Lundemose, who has served as CEO for Bionor Pharma ASA since March 2013. Dr. Lundemose will leave the company to assume the position as CEO in a privately held UK based oncology biotech company.

Bionor Pharma ASA Announces Resignation of Synne Roine as CFO

Bionor Pharma ASA has announced the resignation of Synne Roine as CFO. Ms. Synne H. Roine resigns as CFO in Bionor Pharma ASA to accept an executive position in a private equity held Norwegian based company from April 1, 2015.

Bionor Pharma Announces the Combination of Vacc-4X + Revlimid(R) is Safe and Increases CD4 Counts in People Living with HIV

Bionor Pharma ASA announced the results from the Vacc-4x + Revlimid (lenalidomide) study also known as the "Boost & Kill" study. The Phase II trial was an exploratory double-blind placebo controlled immunogenicity study of Vacc-4x + Revlimid versus Vacc-4x in HIV subjects on ART (HIV standard of care treatment). The study's principal objective was to assess the combination of Vacc-4x + Revlimid in people living with HIV on ART but who have not regained a healthy CD4 level. Twenty four patients were randomized into two groups where one group received Vacc-4x + placebo and one group received Vacc-4x + Revlimid. Patients received six cycles of Vacc-4x vaccination with Revlimid or placebo over a 13 week period. Key endpoints were observed at week 13 and at week 26 (study end). CD4 counts, the key primary efficacy endpoint, increased in both groups. The increase was in the Vacc-4x + Revlimid group where CD4 count increased by 30% (p=0.009) from baseline. In the Vacc-4x + placebo group the CD4 count increased with 17% (p=0.10). However, this was an exploratory study, with a limited number of patients and no statistical difference was observed between the two groups. The three other primary endpoints investigating immune response were T-cell response to Vacc-4x, antibody titer to Vacc-4x peptides and p24, and assessment of antibody titers to a commonly used tetanus toxoid. These immune markers supported the quantitative findings of the CD4 cells. Only one serious adverse event was observed and deemed unrelated to treatment and overall both Vacc-4x and the combination treatment of Vacc-4x + Revlimid were safe and well tolerated. The Phase I/II trial was an exploratory double-blind placebo controlled immunogenicity study of Vacc-4x + Revlimid (lenalidomide) versus Vacc-4x with an initial open label dose escalation assessment of lenalidomide in HIV infected subjects on antiretroviral therapy, ART (SOC HIV treatment). Part A, the Phase I part of the trial, was an open label dose escalation assessment of lenalidomide, showed that all three doses tested were well tolerated, and the higher dose has been chosen for Part B of the study. Part B was a double-blinded placebo controlled parallel design, multicenter study. Both parts were in HIV infected subjects who are on ART but have not fully regained a healthy CD4 level (CD4 counts > 200x10(6) /mL and < 500x10(6) /mL. The trial was conducted in four centers in Germany. The primary objective of this study is in Part A to establish the maximum tolerated dose of lenalidomide and in Part B to evaluate the immunomodulatory effect of lenalidomide under immunization with Vacc-4x (Vacc-4x + lenalidomide versus Vacc-4x + placebo) on CD4 counts, T-cell response to Vacc-4x and assessment of antibody titer to Vacc-4x peptides and p24, and four vaccine peptides to a non-HIV vaccine antigen (tetanus toxoid antibody titer) as measured from week 21 to week 26. Study period for part B, Phase II of the trial, was 26 weeks (13 weeks immunization period + 13 weeks follow-up). Twenty four patients were randomized into two groups where one group received Vacc-4x + placebo and one group received Vacc-4x + Revlimid. Patients received six cycles of Vacc-4x vaccination with Revlimid or placebo over a 13 week period. Key endpoints were observed at week 13 and at week 26. During treatment period all patients remained on ART and received six immunizations (four primary immunizations and two booster immunizations) at weeks 1, 2, 3 and 4 and booster immunizations at weeks 12 and 13 with either Vacc-4x +lenalidomide or placebo over a 13 week period. Key endpoints were observed at week 13 and at week 26 (study end). The patients received lenalidomide or placebo two days prior and on each day of vaccination. One serious adverse event reported (SAE) in this study was a case of subcutaneous abscess that appeared 45 days after the patient was vaccinated. The SAE was evaluated and classified as unrelated by study investigators. The overall clinical and laboratory tolerance profile was satisfactory.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIONOR:NO 2.33 NOK +0.05

BIONOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIONOR.
View Industry Companies
 

Industry Analysis

BIONOR

Industry Average

Valuation BIONOR Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 203.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIONOR PHARMA ASA, please visit www.nutripharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.